Journal of Pharmacy Practice. 30(3):324–328, JUN 2017

DOI: 10.1177/0897190016642689

,  

PMID: 27067742

Issn Print: 0897-1900

Publication Date: 2017/06/01


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

Dosing Practices of Intravenous Acyclovir for Herpes Encephalitis in Obesity: Results of a Pharmacist Survey

Catherine Millares-Sipin;Adrian Wong;Aaron Pickering;Brian Potoski;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Background:Dosing of intravenous acyclovir for herpes encephalitis in obese patients is recommended to be based on ideal body weight. However, limited data support this recommendation, and recent data suggest this may lead to underdosing.Objective:To determine national dosing practices of intravenous acyclovir across a range of patient weights.Methods:A survey was distributed to members of the American College of Clinical Pharmacy Critical Care and Infectious Diseases Practice & Research Networks listservs. Data collected included demographic information and dosing of acyclovir, given consistent patient cases with varying patient weight.Results:A total of 264 pharmacists participated in the survey, with 240 (90.9%) participants completing the survey. Participants were predominately clinical pharmacists. As patient weight increased, respondents were more apt to dose based on an adjusted body weight, with dosing in the obese and morbidly obese showing a clear lack of consistency.Conclusions:Intravenous dosing of acyclovir for herpes encephalitis is variable, especially in obese patients, and does not reflect recommendations. Limited data provide conflicting recommendations for dosing in obese patients, and future studies are necessary to optimize patient outcomes and prevent toxicity.

Related Topics

        loading  Loading Related Articles